Plasma cell lysate as an antigen source in multiple myeloma immunotherapy.
Ritchie
David S
DS
Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre, East Melbourne, Australia. david.ritchie@petermac.org
D000951:Antigens, Neoplasm / Q000737:chemistry*; D019496:Cancer Vaccines / Q000737:chemistry; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D007371:Interferon-gamma / Q000378:metabolism; D008495:Medical Oncology / Q000379:methods; D008954:Models, Biological; D009101:Multiple Myeloma / Q000276:immunology* / Q000628:therapy*; D010950:Plasma Cells / Q000166:cytology / Q000276:immunology*; D053668:Syndecan-1 / Q000096:biosynthesis; D013601:T-Lymphocytes / Q000378:metabolism
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D053668:Syndecan-1; D007371:Interferon-gamma